Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE Natural Killer /T-cell Lymphoma

NCT04366128 is registered in ClinicalTrials.gov with Rong Tao as lead sponsor.

NCT NCT04366128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04366128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE Natural Killer /T-cell Lymphoma
Lead sponsor
Rong Tao
Phase
Not applicable
Overall status
Completed
Start date
April 25, 2020
Completion date
December 30, 2024
Enrollment
61 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

natural killer/t-cell lymphoma, nasal and nasal-type